Quantum-Si GC Lapointe sells $17,795 in shares

Published 24/09/2025, 23:36
Quantum-Si GC Lapointe sells $17,795 in shares

Christian LaPointe, General Counsel and Corporate Secretary of Quantum-Si Inc (NASDAQ:QSI), sold 10,728 shares of Class A Common Stock on September 22 and 23, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as QSI, currently valued at $327 million, has shown significant price momentum with a 28% gain over the past week, according to InvestingPro data.

The sales, executed in two tranches, totaled $17,795. On September 22, 5,364 shares were sold at a weighted average price of $1.6826, with prices ranging from $1.64 to $1.72. The following day, September 23, another 5,364 shares were sold at a weighted average price of $1.635, with prices ranging from $1.57 to $1.79. These transactions occurred as the stock trades within its 52-week range of $0.61 to $5.77, with InvestingPro analysis indicating high price volatility.

The sales were executed to cover tax obligations related to the vesting of restricted stock units. Following the transactions, LaPointe directly owns 960,806 shares of Quantum-Si Inc. Get access to 10+ additional InvestingPro Tips and comprehensive analysis for QSI through the InvestingPro research report, part of our coverage of 1,400+ US stocks.

In other recent news, Quantum-Si Incorporated reported its second-quarter earnings for 2025, showing a mixed financial performance. The company recorded an earnings per share (EPS) of -$0.16, which was slightly below the forecasted -$0.14. Despite this, Quantum-Si achieved a revenue surprise, exceeding expectations by 15.7%, although the actual revenue of $591,000 still fell short of some estimates. In addition to the earnings report, Quantum-Si launched its V4 Sequencing Kit, which is compatible with both its Platinum and Platinum Pro instruments. This new kit enhances protein analysis capabilities with improved sequencing coverage, including glycine recognition and an enzyme designed to cut through amino acids directly preceding proline. These developments reflect the company’s ongoing efforts to advance its technological offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.